Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: Association with a decrease in plasminogen activator inhibitor 1

Experimental and Clinical Endocrinology and Diabetes

Volumn 112, Issue 4, 2004, Pages 175-180

  Aso, Yoshimasa ^a   Okumura, K I ^a   Yoshida, N ^a   Tayama, K ^a   Takemura, Y ^a   Inukai, T ^a  

^a DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fibrinolysis; Glycemic control; Plasmin 2 antiplasmin; Plasminogen activator inhibitor 1; Type 2 diabetes

Indexed keywords

ALPHA 2 ANTIPLASMIN; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HUMAN; INSULIN TREATMENT; LIPID BLOOD LEVEL; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; AGED; ANTIPLASMIN; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FEMALE; FIBRINOLYSIS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA COMPOUNDS;

EID: 2442536913     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-817965     Document Type: Article

References (36)

1. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor I by the human hepatocellular cell line HepG2. Thromb Haemost 1988; 89: 491-494
2. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867
3. Aso Y, Matsumoto S, Fujiwara Y, Tayama K, Inukai T, Takemura Y. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor 1. Metabolism 2002; 51: 471-476
4. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72
5. Bagg W, Ferri C, Desideri G, Gamble G, Ockelford P, Braatvedt GD. The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 5491-5497
6. Bahru Y, Kesteven P, Alberti KG, Walker M. Decreased plasminogen activator inhibitor-1 activity in newly diagnosed type 2 diabetic patients following dietary modification. Diabetic Med 1993; 10: 802-806
7. Calles-Escadon J, Ballor D, Harvey-Berino J, Ades P, Tracy R, Sobel B. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Am J Clin Nutr 1996; 64: 7-11
8. Chen YO., Su M, Walia RR, Hao Q, Convington JW, Vaughan DE. Sp1 sites mediate activation of the plasminogen-activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 1998; 273: 8225-8233
9. DeFronzo RA. Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: a balanced overview. Diabetologia 1992; 35: 389-397
10. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type 11 diabetes. Diabetes Care 1996; 19: 64-66
11. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
12. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycemic control. Diabetic Med 1993; 10: 27-32
13. Jarvi AE, Karlstrom BE, Granfeldt YE, Bjorck IE, Asp NG, Vessby BO. Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients. Diabetes Care 1999; 22: 10-18
14. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462
15. Juhan-Vague I, Alessi MC, Vague P. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13: 1865-1873
16. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin. Thromb Haemost 1989; 61: 370-373
17. Kannel WB, MacGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2: 120-126
18. Kruithof EKO, Tran-Tang C, Bachman F. The fast acting inhibitor of tissue-type plasminogen activator in plasma is also the primary inhibitor of urokinase. Thromb Haemost 1986; 55: 65-69
19. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and lean and obese normal subjects. Diabetes 2000; 49; 633-639
20. Lormeau B, Aurousseau MH, Valensi P, Paries J, Attali JR. Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients. Metabolism 1997; 46: 1074-1079
21. Marvi A, Stegnar M, Krebs M, Sentocnik JT, Geiger M, Binder BR. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arteriorscler Thromb Vasc Biol 1999; 19: 1582-1587
22. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104-109
23. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16: 621-629
24. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose tolerance. Diabetes 1979; 28: 1039-1057
25. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13: 1822-1828
26. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91: 764-770
27. Panahloo A, Mohamed-Ali V, Andres C, Denver AE, Yudkin JS. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metabolism 1998; 47: 637-643
28. Relimpio F, Losada F, Pumar A, Garcia de Pesquera F, Morales F, Acosta D, Astorga R. Relationships of C-peptide levels and the C-peptide/blood sugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type2 diabetic patients. Diabetes Res Clin Pract 1997; 36: 173-180
29. Rossetti L. Glucose toxicity: effects of chronic hyperglycemia on insulin action. In: LeRoith D, Taylor SI, Olefsky JM (Eds). Diabetes Mellitus - a Fundamental and Clinical Text. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 641-651
30. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type 11 diabetic patients. Diabetes 1993; 42: 1-7
31. Schneider DJ, Nordt TK, Sobel BE. Stimulation of proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 1992; 41: 890-895
32. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease. Nature Med 1996; 2: 800-803
33. Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in cardiovascular disease. J Invest Med 1998; 46: 370-376
34. Vukovich T, Proidl S, Knobl P, Teufelsbauer H, Schnack C, Schernthaner G. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients. Thromb Haemost 1992; 68: 253-256
35. Walmsely D, Hampton KK, Grant PJ. Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes. Diabetic Med 1991; 8: 954-959
36. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Haemost 1990: 26: 207-216